Selling safety - Lessons from muraglitazar

[1] Muraglitazar, a dual (α/γ) PPAR activator:: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes [J]. CLINICAL THERAPEUTICS, 2005, 27 (08) : 1181 - 1195

[2] Davies P, 2005, WALL STREET J, pD7

[3] Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes - A retrospective cohort study [J]. DIABETES CARE, 2003, 26 (11) : 2983 - 2989

[4] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J]. LANCET, 2005, 366 (9493) : 1279 - 1289

[5] Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (20): : 2581 - 2586

[6] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [J]. LANCET, 1998, 352 (9131) : 837 - 853

[1] Muraglitazar, a dual (α/γ) PPAR activator:: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes [J]. CLINICAL THERAPEUTICS, 2005, 27 (08) : 1181 - 1195

[2] Davies P, 2005, WALL STREET J, pD7

[3] Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes - A retrospective cohort study [J]. DIABETES CARE, 2003, 26 (11) : 2983 - 2989

[4] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J]. LANCET, 2005, 366 (9493) : 1279 - 1289

[5] Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (20): : 2581 - 2586

[6] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [J]. LANCET, 1998, 352 (9131) : 837 - 853